Figure 4.
KRAS mutation types observed in primary pancreatic adenocarcinomas and primary lung adenocarcinomas. (a) Aminoacid mutations (b) KRAS transition (substitution of a purine for a purine or a pyrimidine for a pyrimidine) and transversion (substitution of a pyrimidine for a purine or purine for a pyrimidine) mutations.